Latest Market Research Reports

  Liquid biopsy is transforming the landscape of cancer diagnostics by offering a minimally invasive alternative to traditional tissue biopsies. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in bodily fluids such as blood, liquid biopsy enables early detection, real-time monitoring, and personalized treatment planning. As precision medicine gains traction, liquid biopsy technologies are becoming integral to modern oncology and clinical decision-making. The global  liquid biopsy market  size was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. The industry is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics. Liquid Biopsy Liquid biopsy refers to the analysis of tumor-derived materials in b...

  Organizations across the healthcare and life sciences sectors are experiencing a transformative shift driven by advancements in molecular diagnostics and precision medicine. Among these innovations, liquid biopsy has emerged as a groundbreaking technology that enables non-invasive disease detection and monitoring using bodily fluids such as blood. Unlike conventional tissue biopsies, liquid biopsy offers a safer, faster, and more dynamic approach to understanding disease progression, particularly in oncology. Liquid biopsy works by analyzing biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles. These biomarkers provide valuable insights into genetic mutations, tumor evolution, and treatment response. As a result, clinicians can make more informed decisions without subjecting patients to invasive procedures. Technological advancements in next-generation sequencing (NGS), digital PCR, and bioinformatics are significantly enhan...